Probiotics for Cardiovascular Protection

Using genetically-engineered microbes and their byproducts to lower cholesterol levels and reduce the risk of high cholesterol and associated diseases. The microbes are engineered to express enzymes called cholesterol oxidoreductases that metabolize cholesterol into coprostanol, a less absorbable form. The microbes can be delivered as probiotics or coprostanol and related compounds can be administered to reduce serum cholesterol levels.

Source

Using Faecalibacterium prausnitzii bacteria as a medicine to treat pathological ventricular remodeling and heart failure following a heart attack.

Source

Probiotic compositions containing specific strains of Lactobacillus bacteria (L. reuteri GMNL-89 and L. paracasei GMNL-133) for preventing stroke and mitigating the severity of stroke. The probiotics are taken as a dietary supplement to regulate intestinal microbiota, enhance intestinal barrier function, and reduce inflammatory responses to prevent ischemic stroke.

Source

Probiotic composition containing specific strains of bacteria that when combined reduce cholesterol and triglycerides in the blood. The composition includes Bifidobacterium lactis MN-Gup, Bifidobacterium lactis M8, Lactobacillus plantarum LP6, and Lactobacillus casei Zhang. The strains can be used to prevent, alleviate, or improve symptoms of high cholesterol and high triglycerides.

Source

A natural composition to support cardiovascular health by contributing to healthy serum cholesterol levels, reducing CRP and IL-6 cytokine levels, and promoting a healthy gut microbiome. The composition includes probiotic bacteria (Lactobacillus plantarum or Lactobacillus reuteri), cholesterol-lowering plant sterols, and Ashwagandha root powder.

Source

Using Bifidobacterium longum strain CCFM752 to prevent and treat cardiovascular diseases, especially hypertension. The strain has been found to significantly reduce blood pressure in hypertensive rats and decrease the levels of reactive oxygen species (ROS) that contribute to hypertension.

Source

A combination of Bacteroides vulgatus and Bacteroides dorei bacteria species, that can control LPS production by enteric bacteria and transfer thereof into the blood. This can reduce intestinal LPS levels, strengthen tight junctions in the intestinal barrier to reduce blood LPS levels, and suppress inflammatory responses and immune responses in intestines, blood vessels, and organs by co-existing in the intestines. It can provide a new way to prevent and improve circulatory diseases, inflammatory diseases, and metabolic diseases through ingestion of these bacteria.

Source

A method for making fermented rice and flour food like steamed cake that is heated to cook in a microwave. The method involves fermenting the batter with sourdough before microwaving. The fermentation process modifies the dielectric properties of the batter to improve the microwave heating and quality of the final product. The fermentation is done to specific conditions to adjust the dielectric constant, loss factor, moisture content, and water activity.

Source

A combination of three probiotic strains, Bifidobacterium animalis WHH2276, Lactobacillus rhamnosus WHH1155, and Lactobacillus fermentum WHH3906, that synergistically lower blood lipids. The strains were selected based on their individual functions of reducing blood lipids, weight, and uric acid. Compared to single strains, the combination showed enhanced blood lipid-lowering effects. This synergy was confirmed through in vitro experiments. The combination is useful in preventing or treating hyperlipidemia-related diseases and symptoms.

Source

Producing antihypertensive peptide compositions from milk using fermentation to hydrolyze peptides. The process involves fermenting milk with Lactobacillus helveticus and a peptidase to partially hydrolyze the peptides, then heat-treating to inactivate the bacteria and peptidase. This creates a fermented milk product containing hydrolyzed peptides with high antihypertensive activity.

Source

Use of Faecalibacterium prausnitzii, a bacteria commonly found in the intestines of mammals, in preparing a medicine for treating pathological ventricular remodeling and/or heart failure following myocardial infarction. The bacteria can improve cardiac function, reduce fibrosis, and inhibit hypertrophy after infarction.

Source

Functional food products for preventing non-communicable diseases like obesity, atherosclerosis, and type 2 diabetes by targeting intestinal microbiota correction. The products contain probiotic bacteria isolated from traditional dishes/drinks and natural prebiotics from fruits/vegetables. The bacteria strains, like Lactobacillus plantarum and Lactobacillus casei, are co-cultured with prebiotic compounds like apple pectin. This synergistic combination selectively inhibits pathogenic bacteria while promoting beneficial bacteria. The products aim to regulate intestinal microbiota for disease prevention through specific microbiota modulation.

Source

Preventative treatment to mitigate negative health effects of air travel on the body. The treatment involves consuming specific substances before and during flights to counteract issues like dehydration, blood thickening, gas expansion, and bacterial overgrowth. The substances include oral rehydration solutions, anticoagulants, probiotics, simethicone (for gas), and domperidone (for motility).

Source

Diagnosing early stage degenerative mitral valve disease in a canine by measuring the normalized relative abundance of specific gut bacteria genera: Erysipelatoclostridium, Ruminococcaceae UCG014, Butyricicoccus, and Faecalibacterium. If Erysipelatoclostridium is 0-0.5, Ruminococcaceae UCG014 is 0-0.1, Butyricicoccus is 0-0.1, or Faecalibacterium is 0-0.1, it indicates early stage DMVD. Administering targeted probiotics like Butyricicoccus or Faecalibacterium to treat or slow progression of DMVD in canines.

Source

Reducing or eliminating specific bacteria from the gut microbiome to prevent or treat myocarditis and dilated cardiomyopathy. The targeted bacteria are Bacteroides, specifically strains that produce mimic peptides of heart muscle proteins. The method involves using antibiotics, bacteriocins, phages, engineered bacteria or other means to selectively kill or reduce the growth of these Bacteroides in the gut. This reduces the risk of autoimmune heart damage by preventing cross-reactive T cells from being activated by the mimic peptides.

Source

A multi-nutrient composition for treating and preventing oxidative stress conditions like cardiovascular disease. The composition includes vitamins, minerals, antioxidants, amino acids, probiotics, and other components.

Source

Composition containing lactic acid bacteria that can reduce heart rate when ingested. The lactic acid bacteria are generally from the Lactobacillus genus, and have specific activities like lowering IL-6 levels and boosting IL-10 production.

Source

Using a specific strain of Lactobacillus fermentum called LM1016 to prevent, ameliorate, and treat cardiovascular diseases, obesity, fatty liver, and diabetes mellitus without side effects. The LM1016 strain reduces levels of cardiovascular disease markers like CRP, neutral fat, and cholesterol, as well as body weight, fat accumulation, inflammation, blood sugar, insulin, and leptin levels. Administering LM1016 has potential as a natural alternative to drugs for managing these chronic conditions.

Source

Reducing corn-on-corn yield penalty in agricultural production. The method involves applying an inoculant containing Penicillium bilaii to corn seeds and/or fields before planting consecutive seasons of corn. The inoculant reduces the yield decrease that usually occurs when planting corn after corn.

Source

A novel strain of Lactobacillus fermentum, LM1016, that can treat or prevent cardiovascular diseases, obesity, fatty liver and diabetes. The strain was found to reduce levels of C-reactive protein, cholesterol, neutral fat, blood sugar, and insulin while inhibiting weight gain and fatty liver development. Administering LM1016 can prevent or treat these chronic conditions.

Source